PT1365762E - Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico - Google Patents

Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico Download PDF

Info

Publication number
PT1365762E
PT1365762E PT02721337T PT02721337T PT1365762E PT 1365762 E PT1365762 E PT 1365762E PT 02721337 T PT02721337 T PT 02721337T PT 02721337 T PT02721337 T PT 02721337T PT 1365762 E PT1365762 E PT 1365762E
Authority
PT
Portugal
Prior art keywords
nicotinic acid
leptin levels
acid compounds
increasing leptin
increase
Prior art date
Application number
PT02721337T
Other languages
English (en)
Inventor
Elaine Jacobson
Myron K Jacobson
Hyuntae Kim
Original Assignee
Univ Kentucky Res Found
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1365762(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found, Univ Arizona filed Critical Univ Kentucky Res Found
Publication of PT1365762E publication Critical patent/PT1365762E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02721337T 2001-03-08 2002-03-08 Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico PT1365762E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08

Publications (1)

Publication Number Publication Date
PT1365762E true PT1365762E (pt) 2008-11-27

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02721337T PT1365762E (pt) 2001-03-08 2002-03-08 Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico

Country Status (13)

Country Link
US (2) US6750234B2 (pt)
EP (1) EP1365762B1 (pt)
JP (1) JP5057353B2 (pt)
CN (1) CN1265792C (pt)
AT (1) ATE409037T1 (pt)
CA (1) CA2437844C (pt)
DE (1) DE60229041D1 (pt)
DK (1) DK1365762T3 (pt)
ES (1) ES2315358T3 (pt)
HK (1) HK1065941A1 (pt)
MX (1) MXPA03008096A (pt)
PT (1) PT1365762E (pt)
WO (1) WO2002072092A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284364B2 (en) 2000-07-31 2006-09-28 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
PT1365762E (pt) * 2001-03-08 2008-11-27 Univ Kentucky Res Found Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
KR101188292B1 (ko) * 2002-11-27 2012-10-09 디엠아이 바이오사이언시스, 인크 인산화 증가로 인한 질병 및 증상의 치료방법
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
EP1810409A4 (en) 2004-10-14 2012-07-04 Qualcomm Inc METHOD AND DEVICES FOR DETERMINING, TRANSMITTING AND USING INFORMATION THAT MAY BE USED FOR TROUBLESHOOTING PURPOSES
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
SI1898867T1 (en) * 2005-06-24 2018-03-30 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona A method for treating hair growth disorders, such as a female pattern of alopecia and the compositions to be used
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8989084B2 (en) 2005-10-14 2015-03-24 Qualcomm Incorporated Methods and apparatus for broadcasting loading information corresponding to neighboring base stations
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US20070249360A1 (en) 2005-12-22 2007-10-25 Arnab Das Methods and aparatus related to determining, communicating, and/or using delay information in a wireless communications system
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
JP5051471B2 (ja) * 2006-08-31 2012-10-17 智 板見 休止期脱毛症治療剤
AU2008219633B2 (en) * 2007-02-28 2011-05-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
CN109414424A (zh) * 2016-04-22 2019-03-01 无锡杰西医药股份有限公司 异硫氰酸酯类化合物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
EP0182635B1 (en) * 1984-11-15 1989-05-31 Nitto Denko Corporation Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
DK0573568T3 (da) * 1991-03-01 2001-04-23 Univ Florida Anvendelse af nicotinære analoger til behandling af degenerative sygdomme i nervesystemet
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
CA2215387A1 (en) * 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
US6015821A (en) * 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
WO1999059614A1 (en) * 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
WO2000032179A2 (en) * 1998-12-01 2000-06-08 University Of Kentucky Research Foundation Use of nicotonic acid derivatives for the treatment of dna damage in skin cells
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
PT1365762E (pt) * 2001-03-08 2008-11-27 Univ Kentucky Res Found Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico

Also Published As

Publication number Publication date
CN1265792C (zh) 2006-07-26
JP2004519488A (ja) 2004-07-02
EP1365762A4 (en) 2005-05-25
DE60229041D1 (de) 2008-11-06
CN1496260A (zh) 2004-05-12
MXPA03008096A (es) 2005-10-05
ATE409037T1 (de) 2008-10-15
WO2002072092A1 (en) 2002-09-19
US20020128298A1 (en) 2002-09-12
CA2437844C (en) 2007-05-15
US6750234B2 (en) 2004-06-15
DK1365762T3 (da) 2008-11-17
ES2315358T3 (es) 2009-04-01
CA2437844A1 (en) 2002-09-19
HK1065941A1 (en) 2005-03-11
EP1365762B1 (en) 2008-09-24
US20040198776A1 (en) 2004-10-07
EP1365762A1 (en) 2003-12-03
JP5057353B2 (ja) 2012-10-24

Similar Documents

Publication Publication Date Title
PT1365762E (pt) Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
NO20054476D0 (no) Forbindelser for behandling av smerte
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
MY134841A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
PL347469A1 (en) Use of certain drugs for treating nerve root injury
AU3831301A (en) Method for treating ocular pain
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2001049275A3 (en) Methods and compositions for mitigating pain using nitrate esters
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2005082375A3 (en) Treatment of interstitial cystitis with vitamin d compounds
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
AP2001002248A0 (en) Method for treating COPD.
NZ519722A (en) Treatment of diabetic ulcers
TW200600084A (en) Anti-coronavirus compounds
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
HK1061355A1 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders